EDGEWISE THERAPEUTICS INC (EWTX)

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Notable Tuesday Option Activity: LULU, EWTX, SNOW

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

One of the biopharma company's heart drugs performs as well as initially hoped.

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip

Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Notable Friday Option Activity: IBKR, EWTX, SLQT

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024

EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edgewise Therapeutics (NASDAQ:EWTX) just reported results for the second quarte...

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

7 Small-Cap Stocks to Buy for Large-Scale Gains

Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.

Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs

What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day

The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024

EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Commit To Buy Edgewise Therapeutics At $12.50, Earn 22.1% Annualized Using Options

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Commit To Purchase Edgewise Therapeutics At $12.50, Earn 19.2% Annualized Using Options